Lipoxin A 4 and benzo-lipoxin A 4 attenuate experimental renal fibrosis

FASEB Journal

Volumn 25, Issue 9, 2011, Pages 2967-2979

  Börgeson, Emma ^a   Docherty, Neil G ^c   Murphy, Madeline ^a   Rodgers, Karen ^a   Ryan, Aidan ^a   O'Sullivan, Tim P ^b   Guiry, Patrick J ^b   Goldschmeding, Roel ^d   Higgins, Debra F ^a   Godson, Catherine ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b University College Dublin   (Ireland)

^c TRINITY COLLEGE DUBLIN   (Ireland)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Eicosanoids; TGF ; Tubulointerstial fibrosis; Unilateral ureteric obstruction

Indexed keywords

BENZO LIPOXIN A; COLLAGEN; GALECTIN 3; GAMMA INTERFERON; GELATINASE A; INTERLEUKIN 10; LIPOXIN A; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; RECOMBINANT ENZYME; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; BENZO LIPOXIN A4; BENZO-LIPOXIN A4; LIPOXIN; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; COLLAGEN METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; FIBROBLAST CULTURE; GENE EXPRESSION; GROWTH INHIBITION; HYDRONEPHROSIS; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY FIBROSIS; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; REPORTER GENE; URETER OBSTRUCTION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG EFFECT; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY DISEASE; LIGATION; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALIA; CHORDATA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; COLLAGEN; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY DISEASES; LIGATION; LIPOXINS; MALE; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 80052680456     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.11-185017     Document Type: Article

References (63)

1. Borgeson, E., and Godson, C. (2010) Molecular circuits of resolution in renal disease. Sci. World J. 10, 1370-1385
2. Lee, S. B., and Kalluri, R. (2010) Mechanistic connection between inflammation and fibrosis. Kidney Int. 78(Suppl. 119), S22-S26
3. Willoughby, D. A., Moore, A. R., Colville-Nash, P. R., and Gilroy, D. (2000) Resolution of inflammation. Int. J. Immunopharmacol. 22, 1131-1135 (Pubitemid 32012972)
4. Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A., Perretti, M., Rossi, A. G., and Wallace, J. L. (2007) Resolution of inflammation: state of the art, definitions and terms. FASEB J. 21, 325-332 (Pubitemid 46213480)
5. Duffield, J. S., Hong, S., Vaidya, V. S., Lu, Y., Fredman, G., Serhan, C. N., and Bonventre, J. V. (2006) Resolvin D series and protectin D1 mitigate acute kidney injury. J. Immunol. 177, 5902-5911 (Pubitemid 44628803)
6. Maderna, P., and Godson, C. (2009) Lipoxins: resolutionary road. Brit. J. Pharmacol. 158, 947-959
7. Serhan, C. N., Yacoubian, S., and Yang, R. (2008) Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol. 3, 279-312 (Pubitemid 351488283)
8. Maderna, P., and Godson, C. (2005) Taking insult from injury: lipoxins and lipoxin receptor agonists and phagocytosis of apoptotic cells. Prostaglandins Leukot. Essent. Fatty Acids 73, 179-187 (Pubitemid 41253474)
9. Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., and Brady, H. R. (2000) Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J. Immunol. 164, 1663-1667 (Pubitemid 30108713)
10. Maderna, P., Cottell, D. C., Toivonen, T., Dufton, N., Dalli, J., Perretti, M., and Godson, C. (2010) FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexinderived peptide-stimulated phagocytosis. FASEB J. 24, 4240-4249
11. Papayianni, A., Serhan, C. N., Phillips, M. L., Rennke, H. G., and Brady, H. R. (1995) Transcellular biosynthesis of lipoxin A4 during adhesion of platelets and neutrophils in experimental immune complex glomerulonephritis. Kidney Int. 47, 1295-1302
12. Leonard, M. O., Hannan, K., Burne, M. J., Lappin, D. W., Doran, P., Coleman, P., Stenson, C., Taylor, C. T., Daniels, F., Godson, C., Petasis, N. A., Rabb, H., and Brady, H. R. (2002) 15-Epi-16-(para-fluorophenoxy)-lipoxin A(4)-methyl ester, a synthetic analogue of 15-epi-lipoxin A(4), is protective in experimental ischemic acute renal failure. J. Am. Soc. Nephrol. 13, 1657-1662 (Pubitemid 34579255)
13. Kieran, N. E., Doran, P. P., Connolly, S. B., Greenan, M. C., Higgins, D. F., Leonard, M., Godson, C., Taylor, C. T., Henger, A., Kretzler, M., Burne, M. J., Rabb, H., and Brady, H. R. (2003) Modification of the transcriptomic response to renal ischemia/reperfusion injury by lipoxin analog. Kidney Int. 64, 480 - 492
14. Badr, K. F., DeBoer, D. K., Schwartzberg, M., and Serhan, C. N. (1989) Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc. Natl. Acad. Sci. U. S. A. 86, 3438-3442 (Pubitemid 19129626)
15. Grumbach, Y., Quynh, N. V., Chiron, R., and Urbach, V. (2009) LXA4 stimulates ZO-1 expression and transepithelial electrical resistance in human airway epithelial (16HBE14o-) cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 296, L101-L108
16. Wu, S. H., Zhang, Y. M., Tao, H. X., and Dong, L. (2010) Lipoxin A(4) inhibits transition of epithelial to mesenchymal cells in proximal tubules. Am. J. Nephrol. 32, 122-136
17. Baker, N., O'Meara, S. J., Scannell, M., Maderna, P., and Godson, C. (2009) Lipoxin A4: anti-inflammatory and antiangiogenic impact on endothelial cells. J. Immunol. 182, 3819-3826
18. McMahon, B., Mitchell, D., Shattock, R., Martin, F., Brady, H. R., and Godson, C. (2002) Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 16, 1817-1819
19. Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., and Madara, J. L. (1995) Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34, 14609-14615 (Pubitemid 3000720)
20. O'Sullivan, T. P., Vallin, K. S., Shah, S. T., Fakhry, J., Maderna, P., Scannell, M., Sampaio, A. L., Perretti, M., Godson, C., and Guiry, P. J. (2007) Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities. J. Med. Chem. 50, 5894-5902
21. Petasis, N. A., Keledjian, R., Sun, Y. P., Nagulapalli, K. C., Tjonahen, E., Yang, R., and Serhan, C. N. (2008) Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties. Bioorg. Med. Chem. Lett. 18, 1382-1387 (Pubitemid 351226538)
22. Duffy, C. D., Maderna, P., McCarthy, C., Loscher, C. E., Godson, C., and Guiry, P. J. (2010) Synthesis and biological evaluation of pyridine-containing lipoxin A4 analogues. Chem. Med. Chem. 5, 517-522
23. Sun, Y. P., Tjonahen, E., Keledjian, R., Zhu, M., Yang, R., Recchiuti, A., Pillai, P. S., Petasis, N. A., and Serhan, C. N. (2009) Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs. Prostaglandins Leukot. Essent. Fatty Acids 81, 357-366
24. Schieppati, A., and Remuzzi, G. (2005) Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int. Suppl. 98, S7-S10
25. Okada, H., and Kalluri, R. (2005) Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr. Mol. Med. 5, 467-474 (Pubitemid 41093560)
26. Liu, Y. (2006) Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 69, 213-217
27. Liu, Y. (2004) Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 15, 1-12
28. Chevalier, R. L., Forbes, M. S., and Thornhill, B. A. (2009) Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75, 1145-1152
29. Higgins, D. F., Kimura, K., Bernhardt, W. M., Shrimanker, N., Akai, Y., Hohenstein, B., Saito, Y., Johnson, R. S., Kretzler, M., Cohen, C. D., Eckardt, K. U., Iwano, M., and Haase, V. H. (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest. 117, 3810-3820 (Pubitemid 350224091)
30. Ma, F. Y., Liu, J., Kitching, A. R., Manthey, C. L., and Nikolic-Paterson, D. J. (2009) Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am. J. Physiol. Renal Physiol. 296, F177-F185
31. Livak, K. J., and Schmittgen, T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2[-Delta Delta C(T)] method. Methods 25, 402-408 (Pubitemid 34164012)
32. Murphy, M., Crean, J., Brazil, D. P., Sadlier, D., Martin, F., and Godson, C. (2008) Regulation and consequences of differential gene expression in diabetic kidney disease. Biochem. Soc. Trans. 36, 941-945
33. Docherty, N. G., Calvo, I. F., Quinlan, M. R., Perez-Barriocanal, F., McGuire, B. B., Fitzpatrick, J. M., and Watson, R. W. (2009) Increased E-cadherin expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int. 75, 205-213
34. Rodriguez-Pena, A. B., Grande, M. T., Eleno, N., Arevalo, M., Guerrero, C., Santos, E., and Lopez-Novoa, J. M. (2008) Activation of Erk1/2 and Akt following unilateral ureteral obstruction. Kidney Int. 74, 196-209 (Pubitemid 351915085)
35. Xia, Z., Abe, K., Furusu, A., Miyazaki, M., Obata, Y., Tabata, Y., Koji, T., and Kohno, S. (2008) Suppression of renal tubulointerstitial fibrosis by small interfering RNA targeting heat shock protein 47. Am. J. Nephrol. 28, 34-46 (Pubitemid 350126491)
36. Xie, Y., Sakatsume, M., Nishi, S., Narita, I., Arakawa, M., and Gejyo, F. (2001) Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int. 60, 1645-1657 (Pubitemid 32999968)
37. Yoo, K. H., Thornhill, B. A., Forbes, M. S., Coleman, C. M., Marcinko, E. S., Liaw, L., and Chevalier, R. L. (2006) Osteopontin regulates renal apoptosis and interstitial fibrosis in neonatal chronic unilateral ureteral obstruction. Kidney Int. 70, 1735-1741 (Pubitemid 44684804)
38. Rooney, B., O'Donovan, H., Gaffney, A., Browne, M., Faherty, N., Curran, S. P., Sadlier, D., Godson, C., Brazil, D. P., and Crean, J. (2011) CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: Implications for the pathogenesis of diabetic nephropathy. FEBS Lett. 585, 531-538
39. De Vries, W. B., Van den Borne, P., Goldschmeding, R., De Weger, R. A., Bal, M. P., Van Bel, F., and Van Oosterhout, M. F. (2010) Neonatal dexamethasone treatment in the rat leads to kidney damage in adulthood. Ped. Res. 67, 72-76
40. Garcia-Sanchez, O., Lopez-Hernandez, F. J., and Lopez-Novoa, J. M. (2010) An integrative view on the role of TGF-beta in the progressive tubular deletion associated with chronic kidney disease. Kidney Int. 77, 950-955
41. Derynck, R., and Zhang, Y. E. (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425, 577-584 (Pubitemid 37280136)
42. Bottinger, E. P. (2007) TGF-beta in renal injury and disease. Sem. Nephrol. 27, 309-320
43. Hewitson, T. D., Ho, W. Y., and Samuel, C. S. (2010) Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 151, 4938-4948
44. Murphy, M., Docherty, N. G., Griffin, B., Howlin, J., McArdle, E., McMahon, R., Schmid, H., Kretzler, M., Droguett, A., Mezzano, S., Brady, H. R., Furlong, F., Godson, C., and Martin, F. (2008) IHG-1 amplifies TGF-beta1 signaling and is increased in renal fibrosis. J. Am. Soc. Nephrol. 19, 1672-1680
45. Yanagita, M. (2006) Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int. 70, 989-993
46. Kieran, N. E., Maderna, P., and Godson, C. (2004) Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 65, 1145-1154 (Pubitemid 38406952)
47. Martins, V., Valenca, S. S., Farias-Filho, F. A., Molinaro, R., Simoes, R. L., Ferreira, T. P., e Silva, P. M., Hogaboam, C. M., Kunkel, S. L., Fierro, I. M., Canetti, C., and Benjamim, C. F. (2009) ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J. Immunol. 182, 5374-5381
48. Docherty, N. G., O'Sullivan, O. E., Healy, D. A., Fitzpatrick, J. M., and Watson, R. W. (2006) Evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am. J. Physiol. 290, F4-F13
49. Serhan, C. N. (2010) Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am. J. Pathol. 177, 1576-1591
50. Wada, T., Furuichi, K., Sakai, N., Iwata, Y., Kitagawa, K., Ishida, Y., Kondo, T., Hashimoto, H., Ishiwata, Y., Mukaida, N., Tomosugi, N., Matsushima, K., Egashira, K., and Yokoyama, H. (2004) Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. J. Am. Soc. Nephrol. 15, 940 -948
51. Sung, S. A., Jo, S. K., Cho, W. Y., Won, N. H., and Kim, H. K. (2007) Reduction of renal fibrosis as a result of liposome encapsulated clodronate induced macrophage depletion after unilateral ureteral obstruction in rats. Nephron Exp. Nephrol. 105, e1-e9 (Pubitemid 46006571)
52. Wang, Y., and Harris, D. C. (2011) Macrophages in renal disease. J. Am. Soc. Nephrol. 22, 21-27
53. Duffield, J. S. (2011) Macrophages in kidney repair and regeneration. J. Am. Soc. Nephrol. 22, 199-201
54. Duffield, J. S. (2003) The inflammatory macrophage: a story of Jekyll and Hyde. Clin. Sci. (Lond.) 104, 27-38
55. Mosser, D. M., and Edwards, J. P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. 8, 958 -969
56. Wang, Y., Wang, Y. P., Zheng, G., Lee, V. W., Ouyang, L., Chang, D. H., Mahajan, D., Coombs, J., Wang, Y. M., Alexander, S. I., and Harris, D. C. (2007) Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease. Kidney Int. 72, 290-299 (Pubitemid 47172367)
57. Cao, Q., Wang, Y., Zheng, D., Sun, Y., Wang, Y., Lee, V. W., Zheng, G., Tan, T. K., Ince, J., Alexander, S. I., and Harris, D. C. (2010) IL-10/TGF-beta-modified macrophages induce regulatory T cells and protect against adriamycin nephrosis. J. Am. Soc. Nephrol. 21, 933-942
58. Mitchell, S., Thomas, G., Harvey, K., Cottell, D., Reville, K., Berlasconi, G., Petasis, N. A., Erwig, L., Rees, A. J., Savill, J., Brady, H. R., and Godson, C. (2002) Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J. Am. Soc. Nephrol. 13, 2497-2507
59. Chiang, N., Takano, T., Arita, M., Watanabe, S., and Serhan, C. N. (2003) A novel rat lipoxin A4 receptor that is conserved in structure and function. Br. J. Pharmacol. 139, 89-98 (Pubitemid 36645312)
60. Phanish, M. K., Wahab, N. A., Colville-Nash, P., Hendry, B. M., and Dockrell, M. E. (2006) The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem. J. 393, 601- 607
61. Suzuki, H., Uchida, K., Nitta, K., and Nihei, H. (2004) Role of mitogen-activated protein kinase in the regulation of transforming growth factor-beta-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin. Exp. Nephrol. 8, 188-195 (Pubitemid 39421367)
62. Cheng, S., Pollock, A. S., Mahimkar, R., Olson, J. L., and Lovett, D. H. (2006) Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 20, 1898-1900
63. Sodin-Semrl, S., Taddeo, B., Tseng, D., Varga, J., and Fiore, S. (2000) Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 164, 2660-2666 (Pubitemid 30115498)